longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

YD Bio

YDES

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 609.35, above the reasonable range, cheaper than 1.53% of the time in the past 1 years, and the industry ranks 67/602, the industry Median -2.44.

609.35xP/E
$2.63Stock price
$0.00Earnings per share
609.35xP/E
Stock price$2.63Earnings per share$0.00

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-375.20x
Typical range
-609.76x–-259.26x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0153306459612

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
BMRNUSBioMarin Pharma
169.93x52.85%$12.40B
YDESUSYD Bio
609.35x--$186.32M
NCELUSNewcelX
311.91x--$17.16M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.